Skip navigation

Biogen Idec Inc.

NAS : BIIB
Pharmaceuticals
Cambridge MA
2013 Revenue (US$ Millions)$5,806
2012 Revenue (US$ Millions)$4,379
Revenue Growth (%)32.61%
Net Income (US$ Millions)$1,862
Common Shares Outstanding (Millions)$236
Earnings Per Share (US$)$7.81
Price To Earnings Ratio295.88
Total Equity (US$ Millions)$8,620
Profit Margin (%)32.08%
Return On Equity (%)26.75%
Long Term Debt (US$ Millions)$592
Debt To Equity Ratio (%)0.07%
Market Capitalization (US$ Millions)$66,072
Total Assets (US$ Millions)$11,863
Return on Assets (%)18.38
Current Assets (US$ Millions)$3,185
Inventories (US$ Millions)$659
Current Liabilities (US$ Millions)$1,758
Cost of Goods Sold (US$ Millions)$858
Asset Turnover0.49
Inventory Turnover1.55
ExchangeNAS